Mineralys Therapeutics, Inc. MLYS Deferred Tax Assets, Goodwill and Intangible Assets

Deferred Tax Assets, Goodwill and Intangible Assets at other companies

Community Financial SystemCBU

$38.5M-2.5%

ePlusPLUS

$3.15M+43.4%

LazardLAZ

$48.15M+4.1%

Amalgamated Financial Corp.AMAL

$240K-39.2%

OFG BancorpOFG

$6.08M+91.9%

Arthur J. GallagherAJG

$560M+216%

Operating income-$45.3M-2.0%

Net income-$39.3M+6.8%

EPS (diluted)-$0.47+40.5%

Cash & equivalents$1.2M-14.6%

Total equity$638.1M+86.8%

Total assets$652.9M+83.9%

Operating cash flow-$39.5M+13.2%

CapEx$15.0K—

Free cash flow-$37.9M+43.3%

Market cap$2.27B+124%

Return on equity-31%-9.6pp

Current ratio44.3×+17.8×

Reported directly by Mineralys Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets.

The official record: Mineralys Therapeutics, Inc.’s 10-K, filed March 12, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Mineralys Therapeutics, Inc.'s deferred tax assets, goodwill and intangible assets?: Mineralys Therapeutics, Inc. (MLYS) reported deferred tax assets, goodwill and intangible assets of $1.82M in Q4 2025.
What is the long-term trend for Mineralys Therapeutics, Inc.'s deferred tax assets, goodwill and intangible assets?: Over 3 years (2022 to 2025), Mineralys Therapeutics, Inc.'s deferred tax assets, goodwill and intangible assets has grown at a 89.0% compound annual growth rate (CAGR), from $270K to $1.82M.